Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus - PubMed (original) (raw)
Clinical Trial
. 2007 May;15(5):1024-33.
doi: 10.1038/mt.sj.6300124. Epub 2007 Mar 13.
Tobias Glaunsinger, Ingrid Stahmer, Volker von Baehr, Christopher Baum, Andrea Schilz, Klaus Kuehlcke, Sonja Naundorf, Holger Martinius, Felix Hermann, Tsanan Giroglou, Sebastian Newrzela, Ingrid Müller, Francis Brauer, Gunda Brandenburg, Alexander Alexandrov, Dorothee von Laer
Affiliations
- PMID: 17356541
- DOI: 10.1038/mt.sj.6300124
Free article
Clinical Trial
Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus
Jan van Lunzen et al. Mol Ther. 2007 May.
Free article
Abstract
Drug toxicity and viral resistance limit the long-term efficacy of antiviral drug treatment for human immunodeficiency virus (HIV) infection. Thus, alternative therapies need to be explored. We tested the infusion of T lymphocytes transduced with a retroviral vector (M87o) that expresses an HIV entry-inhibitory peptide (maC46). Gene-modified autologous T cells were infused into ten HIV-infected patients with advanced disease and multidrug-resistant virus during anti-retroviral combination therapy. T-cell infusions were tolerated well, with no severe side effects. A significant increase of CD4 counts was observed after infusion. At the end of the 1-year follow-up, the CD4 counts of all patients were still around or above baseline. Gene-modified cells could be detected in peripheral blood, lymph nodes, and bone marrow throughout the 1-year follow-up, and marking levels correlated with the cell dose. No significant changes of viral load were observed during the first 4 months. Four of the seven patients who changed their antiviral drug regimen thereafter responded with a significant decline in plasma viral load. In conclusion, the transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus.
Similar articles
- Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus.
Lunzen JV, Glaunsinger T, Stahmer I, Baehr VV, Baum C, Schilz A, Kuehlcke K, Naundorf S, Martinius H, Hermann F, Giroglou T, Newrzela S, Müller I, Brauer F, Brandenburg G, Alexandrov A, von Laer D. Lunzen JV, et al. Mol Ther. 2007 May;15(5):1024-1033. doi: 10.1038/mt.sj.6300124. Epub 2016 Dec 7. Mol Ther. 2007. PMID: 28182893 - Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.
Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC. Morgan RA, et al. Hum Gene Ther. 2005 Sep;16(9):1065-74. doi: 10.1089/hum.2005.16.1065. Hum Gene Ther. 2005. PMID: 16149905 - Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
Macpherson JL, Boyd MP, Arndt AJ, Todd AV, Fanning GC, Ely JA, Elliott F, Knop A, Raponi M, Murray J, Gerlach W, Sun LQ, Penny R, Symonds GP, Carr A, Cooper DA. Macpherson JL, et al. J Gene Med. 2005 May;7(5):552-64. doi: 10.1002/jgm.705. J Gene Med. 2005. PMID: 15655805 Clinical Trial. - Genetic engineering of T cells for adoptive immunotherapy.
Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL. Varela-Rohena A, et al. Immunol Res. 2008;42(1-3):166-81. doi: 10.1007/s12026-008-8057-6. Immunol Res. 2008. PMID: 18841331 Free PMC article. Review. - Gene therapy for pediatric AIDS.
Bauer G, Selander D, Engel B, Carbonaro D, Csik S, Rawlings S, Church J, Kohn DB. Bauer G, et al. Ann N Y Acad Sci. 2000 Nov;918:318-29. doi: 10.1111/j.1749-6632.2000.tb05501.x. Ann N Y Acad Sci. 2000. PMID: 11131719 Review.
Cited by
- Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection.
Maslennikova A, Mazurov D. Maslennikova A, et al. Front Cell Infect Microbiol. 2022 May 25;12:880030. doi: 10.3389/fcimb.2022.880030. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35694537 Free PMC article. Review. - Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients.
Schwarze LI, Sonntag T, Wild S, Schmitz S, Uhde A, Fehse B. Schwarze LI, et al. Gene Ther. 2021 Sep;28(9):572-587. doi: 10.1038/s41434-021-00259-5. Epub 2021 Apr 19. Gene Ther. 2021. PMID: 33867524 Free PMC article. - Retroviral gene therapy in Germany with a view on previous experience and future perspectives.
Morgan MA, Galla M, Grez M, Fehse B, Schambach A. Morgan MA, et al. Gene Ther. 2021 Sep;28(9):494-512. doi: 10.1038/s41434-021-00237-x. Epub 2021 Mar 22. Gene Ther. 2021. PMID: 33753908 Free PMC article. Review. - Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, LentivirusModified CD4 T Cells for HIV Functional Cure.
Li H, Lahusen T, Xiao L, Muvarak N, Blazkova J, Chun TW, Pauza CD. Li H, et al. Mol Ther Methods Clin Dev. 2020 May 3;17:1048-1060. doi: 10.1016/j.omtm.2020.04.024. eCollection 2020 Jun 12. Mol Ther Methods Clin Dev. 2020. PMID: 32462053 Free PMC article. - Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.
Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, Ochsenbauer C, Kappes JC, Krueger W, Worden A, Schneider D, Zhu Z, Orentas R, Dimitrov DS, Goldstein H, Dropulić B. Anthony-Gonda K, et al. Sci Transl Med. 2019 Aug 7;11(504):eaav5685. doi: 10.1126/scitranslmed.aav5685. Sci Transl Med. 2019. PMID: 31391322 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials